Abbott (ABT) Sees Q4 Sales Growth in Low-Mid Single-Digit Range
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Raymond James Downgrades Abbott Labs (ABT) to Market Perform
October 18, 2012 7:51 AM EDTRaymond James downgraded Abbott Labs (NYSE: ABT) from Outperform to Market Perform.
For an analyst ratings summary and ratings history on Abbott Labs click here. For more ratings news on Abbott Labs click here.
Shares of Abbott Labs closed at $69.04 yesterday, with a 52 week range of $51.53-$72.47.... More
Abbott Laboratories (ABT) Tops Q3 EPS by 2c; Narrows FY12 EPS Outlook
October 17, 2012 7:45 AM EDTAbbott Laboratories (NYSE: ABT) reported Q3 EPS of $1.30, $0.02 better than the analyst estimate of $1.28. Revenue for the quarter came in at $9.77 billion versus the consensus estimate of $9.93 billion.
Abbott Laboratories sees FY2012 EPS of $5.06-5.08, versus prior guidance of $5.00-5.10 and the consensus of $5.06.... More
